Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Apo C)
3,042 results
  • Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review. [Review]
    Cardiovasc Diabetol. 2022 12 05; 21(1):272.Rouland A, Masson D, … Bouillet B
  • Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density lipoproteins (VLDL) to VLDL-receptor (VLDL-R), to low density lipoprotein receptor (LDL-R) and to LDL receptor…
  • Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations. [Journal Article]
    Genome Med. 2022 11 23; 14(1):132.Sandholm N, Hotakainen R, … FinnDiane Study Group
  • CONCLUSIONS: We identified lipid and apolipoprotein-associated variants in the previously known LIPC and APOB genes, as well as PAVs in GTF3C5 associated with LDLC, and in RBM47 associated with apolipoprotein C-III concentrations, implicated as an independent CVD risk factor. Identification of rare loss-of-function variants has previously revealed genes that can be targeted to prevent CVD, such as the LDL cholesterol-lowering loss-of-function variants in the PCSK9 gene. Thus, this study suggests novel putative therapeutic targets for the prevention of CVD.
  • Simultaneous Quantification of Apolipoprotein C-III O-Glycoforms by Protein-MRM. [Journal Article]
    J Proteome Res. 2023 Jan 06; 22(1):91-100.Kim H, Cheon DH, … Baek JH
  • Apolipoprotein C-III (APOC-III) regulates triglyceride levels, associated with a risk of cardiovascular disease. One gene generates several proteoforms, each with a different molecular mass and a unique function. Unlike peptide multiple reaction monitoring (MRM), protein-MRM without digestion is required to analyze clinically relevant individual proteoforms. We developed a protein-MRM method with…
  • ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC. [Journal Article]
    Int J Mol Sci. 2022 Oct 24; 23(21)Wang J, Man Q, … Liu B
  • Lymph node metastasis is associated with poor prognosis of oral squamous cell carcinoma (OSCC), and few studies have explored the relevance of postoperative lymphatic drainage (PLD) in metastatic OSCC. Alpha-enolase (ENO1) is a metabolic enzyme, which is related to lymphatic metastasis of OSCC. However, the role of ENO1 in PLD in metastatic OSCC has not been elucidated. Herein, we collected lymph…
  • Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. [Randomized Controlled Trial]
    N Engl J Med. 2022 Nov 24; 387(21):1923-1934.Das Pradhan A, Glynn RJ, … PROMINENT Investigators
  • CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
  • Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study. [Journal Article]
    Sci Rep. 2022 10 10; 12(1):16981.Hilbert M, Kuzman P, … Nestler U
  • Apolipoprotein C1 (ApoC1) has been detected immunohistochemically in glioblastoma tissue, probably expressed by activated monocytes and microglia. The present study was conceived to determine whether the amount of intratumoral ApoC1 expression leads to measurable changes of serum levels after glioblastoma resection or during recurrence. 176 blood samples from 70 glioblastoma patients were collect…
  • Recent Apolipoprotein CIII trials. [Review]
    Curr Opin Lipidol. 2022 12 01; 33(6):309-318.Tramontano D, Bini S, … Arca M
  • This review will briefly revise the evidence concerning the pharmacological inhibition of Apolipoprotein CIII (ApoCIII) in patients with hypertriglyceridemia.
  • Surface charge influences protein corona, cell uptake and biological effects of carbon dots. [Journal Article]
    Nanoscale. 2022 Oct 13; 14(39):14695-14710.Arezki Y, Delalande F, … Ronzani C
  • Carbon dots are emerging nanoparticles (NPs) with tremendous applications, especially in the biomedical field. Herein is reported the first quantitative proteomic analysis of the protein corona formed on CDs with different surface charge properties. Four CDs were synthesized from citric acid and various amine group-containing passivation reagents, resulting in cationic NPs with increasing zeta (ζ…
  • Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen. [Journal Article]
    Cardiol Rev. 2022 Sep 21 [Online ahead of print]Gesner M, Frishman WH
  • Volanesorsen is a new medication that may soon be used in the treatment of hypertriglyceridemia and familial chylomicronemia syndrome (FCS). Volanesorsen works via binding to Apo C-III mRNA and degrading that mRNA, thus decreasing the synthesis of Apo C-III. This decreased synthesis of Apo C-III will increase the binding of triglycerides to LDL receptors and decrease triglyceride plasma levels. I…
  • [Lipid lowering: new agents and new concepts]. [Review]
    Herz. 2022 Oct; 47(5):419-425.Brandts J, Verket M, Müller-Wieland D
  • Low-density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for cardiovascular complications. A target value is set according to risk, guideline-based and individual basis. We now have the means to lower LDL‑C levels to ranges that are even associated with plaque volume regression. Moreover, lipid treatment is an example of how pharmacotherapy has evolved from classical selective in…
New Search Next